A Phase 2 interventional study of Zanubrutinib in Refractory Mantle Cell Lymphoma and Relapsed Mantle Cell Lymphoma, sponsored by BeiGene. Completed at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell — 12 open to participants now, 14 under way, 2 of them phase 3. zanubrutinib · Lymphoma, Mantle-Cell.
Among the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 13 in phase 2, and was the 1st registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →12 of the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell are open now, in 4 countries. Recruiting first, the newest first:
Canadian Cancer Trials Group · Sites in Canada
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Christine Ryan · Sites in United States
Ages 18+
Fudan University · Sites in China
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 2
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 45 across the 17 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Lymphoma, Mantle-Cell by BeOne Medicines: 4 open now, 6 under way, 2 of them phase 3. Of 4 finished, 2 (50%) have results posted.
Among the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 2, and was the 1st registered.
BeOne Medicines’s Lymphoma, Mantle-Cell studies by the year they started, since 2017.
3 of the studies testing zanubrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06504199Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | 2026-12-31 |
| NCT07261163Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | 2027-07-31 |
| NCT06136351Ruijin HospitalA Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among BeOne Medicines’s 10 in Lymphoma, Mantle-Cell:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zanubrutinib (160 milligrams) administered orally twice daily
Drug: Zanubrutinib
Administered as specified in the treatment arm.
Also known as: BGB-3111
Overall Response Rate (ORR) As Assessed By Independent Review Committee
The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR.
Time frame: Up to 1 year and 11 months
Progression-free Survival
Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.
Time frame: Up to 3 years and 6 months
Time To Response
Time to response was defined as the time from treatment initiation to the first documentation of response.
Time frame: Up to 3 years and 6 months
Duration Of Response
The duration of response was defined as the time from the date that the response criteria are first met to the date that Progressive Disease was objectively documented or death (whichever occurs first). Participants who did not have disease progression were censored at their last valid assessment.
Time frame: Up to 3 years and 6 months
ORR As Assessed By The Investigator
The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a BOR of CR or PR. The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR. For this outcome measure, only investigator-assessed data are analyzed and reported because of the high rate of concordance between the Independent Review Committee and investigator assessments for the primary outcome measure of ORR.
Time frame: Up to 3 years and 6 months
Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up visit) or initiation of new anticancer therapy, whichever comes first.
Time frame: From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)
Number Of Participants Experiencing AEs Leading To Treatment Discontinuation
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to the study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)
This study was conducted at 14 study centers in China; 13 study centers enrolled participants. Once the primary and secondary objectives were met and the analysis was complete, sponsor ended the study on 08 September 2020 and transferred all participants remaining on treatment to long term extension study.
| Milestone | Zanubrutinib |
|---|---|
| Started | 86 |
| Received at least 1 dose of study drug | 86 |
| Completed | 0 |
| Not completed | 86 |
| Withdrew: Death | 21 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Primary and secondary objectives were met and remaining participants transferred to lte by sponsor | 49 |
The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR.
| Participants | Zanubrutinib |
|---|---|
| Overall Response Rate (ORR) As Assessed By Independent Review Committee | 72 |
Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.
| months | Zanubrutinib |
|---|---|
| Progression-free Survival | 33.0 (19.4 to NA) |
Time to response was defined as the time from treatment initiation to the first documentation of response.
| months | Zanubrutinib |
|---|---|
| Time To Response | 2.72 ± 0.105 |
The duration of response was defined as the time from the date that the response criteria are first met to the date that Progressive Disease was objectively documented or death (whichever occurs first). Participants who did not have disease progression were censored at their last valid assessment.
| months | Zanubrutinib |
|---|---|
| Duration Of Response | NA (24.9 to NA) |
The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a BOR of CR or PR. The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR. For this outcome measure, only investigator-assessed data are analyzed and reported because of the high rate of concordance between the Independent Review Committee and investigator assessments for the primary outcome measure of ORR.
| Participants | Zanubrutinib |
|---|---|
| ORR As Assessed By The Investigator | 72 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up visit) or initiation of new anticancer therapy, whichever comes first.
| Participants | Zanubrutinib |
|---|---|
| Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs) | 83 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to the study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Zanubrutinib |
|---|---|
| Number Of Participants Experiencing AEs Leading To Treatment Discontinuation | 8 |
Collected over Day 1 through 3 years and 6 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib | 7/86 (8.1%) | 25/86 (29.1%) | 82/86 (95.3%) |
| Event | Zanubrutinib |
|---|---|
| PneumoniaInfections and infestations | 10/86 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/86 |
| DeathGeneral disorders | 2/86 |
| Platelet count decreasedInvestigations | 2/86 |
| AnaemiaBlood and lymphatic system disorders | 1/86 |
| Bone marrow necrosisBlood and lymphatic system disorders | 1/86 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/86 |
| BronchitisInfections and infestations | 1/86 |
| InfectionInfections and infestations | 1/86 |
| Pneumonia fungalInfections and infestations | 1/86 |
| Event | Zanubrutinib |
|---|---|
| Neutrophil count decreasedInvestigations | 39/86 |
| Upper respiratory tract infectionInfections and infestations | 33/86 |
| RashSkin and subcutaneous tissue disorders | 31/86 |
| White blood cell count decreasedInvestigations | 29/86 |
| Platelet count decreasedInvestigations | 28/86 |
| Alanine aminotransferase increasedInvestigations | 16/86 |
| HypokalaemiaMetabolism and nutrition disorders | 15/86 |
| AnaemiaBlood and lymphatic system disorders | 14/86 |
| DiarrhoeaGastrointestinal disorders | 14/86 |
| HypertensionVascular disorders | 13/86 |
Safety Analysis Set: All participants who received any dose of study drug.
| Age, Continuous(years) | Zanubrutinib |
|---|---|
| Mean | 59.0 ± 8.18 |
| Age, Customized(Participants) | Zanubrutinib |
|---|---|
| < 65 years | 64 |
| ≥ 65 years | 22 |
| Sex: Female, Male(Participants) | Zanubrutinib |
|---|---|
| Female | 19 |
| Male | 67 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib |
|---|---|
| Chinese | 86 |
| Region of Enrollment(participants) | Zanubrutinib |
|---|---|
| China | 86 |
| Mantle Cell Lymphoma (MCL) Disease Stage at Study Entry(Participants) | Zanubrutinib |
|---|---|
| MCL Stage I | 1 |
| MCL Stage II | 7 |
| MCL Stage III | 14 |
| MCL Stage IV | 64 |
| Disease Status(Participants) | Zanubrutinib |
|---|---|
| Relapsed Disease | 41 |
| Refractory Disease | 45 |
| Eastern Cooperative Oncology Group Performance Status(Participants) | Zanubrutinib |
|---|---|
| Grade 0 | 60 |
| Grade 1 | 22 |
| Grade 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Mar 2017 to primary completion in Feb 2019, 23 months.
Results were first posted in May 2020, 1 year 2 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 23 months is below that.
Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib